Perspective Therapeutics Inc CATX

Healthcare Biotechnology

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

NYSEAM:CATX - Post by User

Perspective Therapeutics Inc

Bullboard Posts

Post by kingposton May 28, 2015 2:26pm

240 Views

Post# 23774942

Lung, Prostate great results next Brain, Breast and Pancese

This is only the LUNG, they have BRAIN study results that are a home run, presentation on the BRAIN is going to be made on May 29 2015. Much lower LONG TERM side affects on the PROSTATE compared with slightly cheaper I-125 isotope. ISR coming up with delivery mechanisms for C-131 to the BREAST and PANCREATIC cancers. C-131 will be well know very soon in the medical community

Bullboard Posts

Day trading vs. swing trading strategies for small-cap stocks